Clinical trial
Safety of REPEVAX® Given One Month After REVAXIS®
NCT00400309 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00400309 |
|---|---|
| Title | Safety of REPEVAX® Given One Month After REVAXIS® |
| Official title | A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of Repevax® Administered One Month After Revaxis® or Placebo to Healthy Adults |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Healthy Adult |
| Intervention type | Biological |
| Interventions | REPEVAX® after REVAXIS®, REPEVAX® after Placebo |
| Enrollment | 500 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Nov 16, 2006 |
| Last update posted | Sep 11, 2017 |
| Countries | France |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: